Last updated: February 27, 2026
What is the Product?
NDC 46122-0669 corresponds to Tafasitamab-cxix (Monjuvi), a monoclonal antibody indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is administered in combination with lenalidomide, following approval by the U.S. Food and Drug Administration (FDA) in August 2020.
Market Overview
Drug Approval and Indication
- FDA Approval Date: August 2020
- Indication: Treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, including those with disease ineligible for high-dose chemotherapy plus stem cell transplantation.
- Mechanism of Action: Tafasitamab binds to CD19, a B-cell antigen, augmenting antibody-dependent cell-mediated cytotoxicity and phagocytosis.
Competitive Landscape
| Drug |
Indication |
Market Status |
Key Competitors |
Pricing (Approx.) |
| Tafasitamab + Lenalidomide |
Relapsed/refractory DLBCL |
Marketed, first-in-class |
Rituximab, Polatuzumab, Xevudy (Sotrovimab) - not direct competitors |
$12,000–$15,000 per infusion |
| Rituximab (Rituxan) |
Various B-cell cancers |
Widely used, biosimilars exist |
Obinutuzumab, Obinuzumab, Ofatumumab |
~$5,000 per infusion |
| Polatuzumab vedotin |
DLBCL after prior therapy |
Approved, niche drug |
Tafasitamab, Rituximab |
~$10,000–$14,000 per dose |
Market Size
The U.S. lymphoma market was valued at approximately $2.6 billion in 2021. DLBCL cases in the U.S. estimated around 20,000 annually, with about 34% refractory or relapsed cases eligible for Tafasitamab-based therapy.
Market Penetration and Adoption Factors
- Prior Therapies: Patients often receive multiple lines of therapy; Tafasitamab is positioned after at least one prior therapy.
- Combination Regimen: Efficacy data supporting the combination with lenalidomide influences adoption.
- Reimbursement: Payer policies and coverage significantly affect penetration.
- Pricing Strategies: Premium prices maintain exclusivity but may limit access.
Price Projections
Current Pricing
- Per-Unit Cost: Approximately $12,000–$15,000 per infusion (based on commercial pricing data).
- Cost per Treatment Course: Typically 6–8 infusions, totaling $72,000–$120,000.
Short-Term Market Trends (Next 2 Years)
- Pricing Stability: Likely stable, subject to negotiations and rebate arrangements.
- Market Growth: Estimated at 15% annually due to increased adoption, especially in underserved regions.
Long-Term Trends (3–5 Years)
- Price Adjustments: Potential slight declines driven by biosimilar entries and increased competition.
- Market Expansion: Growth of indications in other B-cell malignancies, possibly affecting price and volume.
- Global Pricing: Higher in the U.S., with potential lower prices in European markets due to healthcare policies.
Impact of Biosimilar Competition
- Biosimilars for rituximab have entered multiple markets; no biosimilar for Tafasitamab is on record as of 2023.
- Introduction of competitors could diminish pricing power, especially if similar efficacy is demonstrated.
Regulatory and Policy Influences
- Reimbursement: Centers for Medicare & Medicaid Services (CMS) and private payers influence pricing with formulary decisions.
- ICER and Value Assessments: Cost-effectiveness analyses may lead to negotiations or discounts.
- Patent Status: Patent protections extend at least until 2030, supporting pricing power temporarily.
Financial and Commercial Considerations
- Pricing Strategy: Premium pricing justified by innovation and targeted therapy status.
- Market Demand: Dependent on clinical uptake, awareness, and reimbursement.
- Supply and Distribution: Ensures availability for diagnosed patients.
Key Takeaways
- Tafasitamab-cxix (NDC 46122-0669) is a targeted therapy with a niche but growing market in relapsed/refractory DLBCL.
- The current price per infusion ranges from $12,000 to $15,000, with total course costs reaching $120,000.
- Market growth is driven by increasing lymphoma prevalence and treatment-resistant cases.
- Entry of biosimilars and competitive agents could pressure prices over the next 3–5 years.
- Reimbursement policies and clinical adoption significantly influence actual prices and market share.
FAQs
-
What factors influence Tafasitamab pricing?
Pricing depends on clinical efficacy, manufacturing costs, reimbursement negotiations, and competitive landscape.
-
Are biosimilars expected for Tafasitamab?
As of 2023, no biosimilars are approved or in late-stage development for Tafasitamab.
-
How does the cost compare to other treatments?
Tafasitamab costs are higher than rituximab due to its novel mechanism and targeted approach.
-
What is the potential for price reduction?
Introduction of biosimilars and increased competition could lead to moderate price reductions over the next 3–5 years.
-
What regions will see the highest prices?
The U.S. maintains the highest pricing, with European markets generally experiencing lower costs due to policy pressures.
References
[1] FDA. (2020). FDA approves Monjuvi for relapsed or refractory DLBCL. Retrieved from https://www.fda.gov
[2] IQVIA. (2022). US Oncology Market Data.
[3] EvaluatePharma. (2022). Oncology drug market forecasts.
[4] FDA. (2021). Tafasitamab prescribing information.
[5] Statista. (2022). US lymphoma market size and trends.
